LEADER 01616nam  2200325z- 450 
001 9910796836603321
005 20210112135856.0
010   $a1-58528-581-1
035   $a(CKB)4100000004827102
035   $a(MiAaPQ)EBC5412768
035   $a(EXLCZ)994100000004827102
100   $a20180708cuuuuuuuu  -u-            -
101 0 $aeng
200 10$aBiosimilars and biologics $eimplementation and monitoring in a healthcare setting /$fSteven Lucio
210   $cAmerican Society of Health-System Pharmacists
311   $a1-58528-580-3 
327   $aA new type of blockbuster : the growth of biologics -- De?ja? vu or something new? : comparing the generics and biosimilars experiences -- Bugs and drugs, and yeast and mice, and Chinese hamsters -- The $250 billion pyramid : analytics in biosimilarity determination -- The global biosimilars experience -- The American biosimilar experience : red, white, and possibly interchangeable -- Biosimilar clinical trial requirements -- Immunogenicity and pharmacovigilance in the biosimilar era -- The patent dance and the exclusivity shuffle -- Defining biosimilar value and other impossible tasks -- Biosimilar formulary management strategies.
517   $aBiosimilars and Biologics 
606   $aBiosimilar Pharmaceuticals
606   $aDrug Compounding
606   $aDrug Monitoring
615 12$aBiosimilar Pharmaceuticals
615 22$aDrug Compounding
615 22$aDrug Monitoring
676   $a615.1/9
700   $aLucio$b Steven$01501857
906   $aBOOK
912   $a9910796836603321
996   $aBiosimilars and biologics$93729190
997   $aUNINA